Skip to Main Content

College of Pharmacy

In this section

HelixTalk Episode #125 - Let’s Get Personal: Talking Warfarin Pharmacogenomics

Date posted: January 26, 2021, 6:00 am

In this episode, we will briefly review the clotting cascade and warfarin's mechanism of action, and then discuss warfarin pharmacogenetics implications and what clinical recommendations and tools are available in order to calculate warfarin dose.

 

Key Concepts

  1. Many patient specific factors such as drug interactions, food interactions, genetic polymorphisms, and lifestyle habits are considered in successfully dosing and managing warfarin.
  2. Genetic polymorphisms found in either metabolizing enzyme CYP2C9, target protein VKORC1, or vitamin K oxidase CYP4F2 can alter warfarin phenotype in certain patients.
  3. When genetic test results for polymorphisms are available, they should be utilized for algorithm-based dosing in most patients. Such algorithms have outcomes for better TTR (time in therapeutic range), less out-of-range INRs, and shorter time to therapeutic dose.
  4. Certain polymorphisms are specific to different ancestry and not all commercially available tests check for these pertinent polymorphisms. CPIC guidelines provide further insight into how to use test results to derive a warfarin dose.

References